This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-03. Anything still debated is marked as such rather than presented as settled.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
=== Availability === GGC synthesis for commercial use is exceedingly difficult and, until recently, no commercially viable process for large scale production had been developed. The major drawback preventing the commercial success of chemical synthesis of GGC is the number of steps involved due to the three reactive groups on L-glutamic acid and L-cysteine molecules, which must be masked to achieve the correct regioisomer. Similarly, there have been numerous attempts at biological production of GGC by fermentation over the years and none have been successfully commercialised. Towards the end of 2019, a biocatalytic process was successfully commercialized. GGC is now available as a supplement in the US under the trademarked name of Glyteine and Continual-G.
== History == April 2016: initiation of Phase 2b trial December 2017: initiation of JADE Mono-1 Phase 3 trial May 2018: Results of Phase 2b trial posted October 2019: Results of Phase 3 trial presented June 2020: Results of second Phase 3 trial published The US Food and Drug Administration (FDA) approved abrocitinib based on evidence from three controlled clinical trials enrolling a total of 1615 participants supporting efficacy and safety. Two of the trials enrolled participants twelve years of age and older with moderate-to-severe atopic dermatitis and one trial enrolled adults with moderate-to-severe atopic dermatitis. The trials were conducted at multiple sites in 18 countries (i.e., United States, Canada, Australia, Mexico, Chile, Great Britain, Poland, Germany, Bulgaria, Hungary, Czech Republic, Latvia, Slovakia, Spain, Italy, Japan, Korea, Taiwan). In addition, safety analyses were performed on the combined results of these 3 controlled clinical trials and one additional controlled study in a total of 1,540 participants. All three trials evaluated two doses of abrocitinib: 100 mg and 200 mg. The monotherapy trials were identically designed, 16-week, randomized, multicenter, double-blind, placebo-controlled, parallel group, phase 3 trials. Trial-AD-3 with concomitant background therapy was a 24-week, multicenter, randomized, double-blind, active-comparator (dupilumab) and placebo-controlled, phase 3 trial.
Chain Home, or CH for short, was the codename for the ring of coastal early warning radar stations built by the Royal Air Force (RAF) before and during the Second World War to detect and track aircraft. Initially known as RDF, and given the official name Air Ministry Experimental Station Type 1 (AMES Type 1) in 1940, the radar units were also known as Chain Home for most of their life. Chain Home was the first early warning radar network in the world and the first military radar system to reach operational status. Its effect on the war made it one of the most powerful systems of what became known as the "Wizard War". In late 1934, the Tizard Committee asked radio expert Robert Watson-Watt to comment on the repeated claims of radio death rays and reports suggesting Germany had built some sort of radio weapon. His assistant, Arnold Wilkins, demonstrated that a death ray was impossible but suggested radio could be used for long-range detection. In February 1935, a successful demonstration was arranged by placing a receiver near a BBC short wave transmitter and flying an aircraft around the area. Using commercial short wave radio hardware, Watt's team built a prototype pulsed transmitter and, by June 1935, it detected an aircraft that happened to be flying past. Basic development was completed by the end of the year, with detection ranges on the order of 100 mi (160 km). In 1936, attention was focused on a production version, and early 1937 saw the addition of height finding.
Sources: en.wikipedia.org
=== Lucinda Young === Lucinda Young (Ruby Bentall) is a VP on Pierpoint's Investment Banking Division (IBD), overseeing Gus and Hari. She tacitly encourages Hari to overwork during his first week on the job; after Hari dies of a heart attack, Lucinda feels guilty, and worries whether she will be held culpable for Hari's death, telling Gus to vouch for her with HR. Lucinda is briefly seen in series 2 meeting with executives from healthcare startup Rican, for whom Pierpoint is helping engineer a major trade.
Bukele was president of Yamaha Motors El Salvador, a company that sells and distributes Yamaha products in El Salvador, from 2009 to 2012. During Bukele's business career, he called himself a "businessman with a great future" ("empresario con gran futuro").
The US Treasury declares that it has cut off all Banque Misr's UAE branches from dollar transactions due to its dealings with the Iranian government. August 29 Trump declares that the US reached a deal with Venezuela for controlling 65 billion barrels of its oil reserves. The former White House teleprompter operator Gabriel Perez is ordered by the Commodity Futures Trading Commission to pay $172,000 for using advance access to Trump's speeches to make illegal betting on prediction-market platform Kalshi. A federal court in California rules that Trump cannot deport students who criticize the Israeli war in Gaza. American singer Olivia Rodrigo holds the inaugural charitable Daisy Chain Fields music festival in Irvine, California, U.S., a day after announcing that the festival would donate US$10 million to organizations contributing to women’s rights and reproductive justice. August 30 NASA launches the flagship Nancy Grace Roman Space Telescope aboard a SpaceX Falcon Heavy rocket from the Kennedy Space Center in Florida. Designed to investigate dark energy, dark matter and exoplanets, the observatory has a field of view at least 100 times larger than the Hubble Space Telescope's. U.S. forces state that they targeted two Iranian launchers on Larak Island after IRGC forces were identified preparing to launch rockets carrying sea mines toward the Strait of Hormuz. August 31 Iran claims to have retaliated by attacking U.S. bases in Jordan and U.S. military assets in the United Arab Emirates. Trump promises to respond to the Iranian attack against American soldiers in Jordan.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.